加载中...

MedXY News - immunotherapy

MedXY AI/MedXY News/Tag: immunotherapy

MedXY News

EnglishTag

immunotherapy

138 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Head and Neck Cancer

Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Head and Neck Cancer

A large claims-based study reveals pembrolizumab dominates immunotherapy prescribing for head and neck cancer, with minimal usage growth since FDA approval. Immune-related adverse events occurred in 41.2% of patients, linked to specific com

Section: newsApr 27, 2026

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial

The NIVOLEP phase 2 trial demonstrates that perioperative nivolumab (neoadjuvant and adjuvant) combined with irreversible electroporation achieves 70.6% one-year local recurrence-free survival in BCLC A HCC patients with high recurrence ris

Section: GastroenterologyApr 14, 2026

Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy Rechallenge

Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy Rechallenge

A nationwide French cohort study reveals that advanced NSCLC patients completing 2 years of pembrolizumab maintain excellent survival outcomes, with most remaining treatment-free and immunotherapy rechallenge being uncommon.

Section: newsApr 14, 2026

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location

This retrospective study challenges the assumption that prior radiation limits immunotherapy effectiveness in recurrent endometrial and cervical cancers, finding no significant difference in response rates or survival outcomes based on recu

Section: newsApr 6, 2026

Oncolytic Bovine Herpesvirus Type 1: A Novel Strategy for Immune Microenvironment Remodeling in Multiple Myeloma

Oncolytic Bovine Herpesvirus Type 1: A Novel Strategy for Immune Microenvironment Remodeling in Multiple Myeloma

This review explores the breakthrough potential of Bovine Herpesvirus Type 1 (BoHV-1) as an oncolytic agent in Multiple Myeloma, highlighting its ability to induce mitochondrial apoptosis, reprogram the immunosuppressive bone marrow niche,

Section: Clinical UpdatesApr 6, 2026

Optimizing the Synergy: Sequential vs. Concurrent Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer

Optimizing the Synergy: Sequential vs. Concurrent Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer

This review evaluates the optimal sequencing of radiotherapy and immunotherapy in advanced NSCLC, highlighting real-world evidence from the OCEANUS study favoring sequential over concurrent administration.

Section: Clinical UpdatesApr 3, 2026

Long-Term Survival Milestones in Metastatic Nasopharyngeal Carcinoma: A Comprehensive Review of the 5-Year CAPTAIN-1st Data

Long-Term Survival Milestones in Metastatic Nasopharyngeal Carcinoma: A Comprehensive Review of the 5-Year CAPTAIN-1st Data

This review analyzes the 5-year overall survival outcomes of the CAPTAIN-1st trial, establishing camrelizumab plus chemotherapy as a long-term standard of care for recurrent or metastatic nasopharyngeal carcinoma.

Section: Clinical UpdatesMar 20, 2026

Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results

Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results

This review analyzes the Phase 3 Precision-T trial, demonstrating that Orca-T, a high-precision T-cell therapy, significantly improves chronic GVHD-free survival and reduces non-relapse mortality compared to standard-of-care prophylaxis in

Section: Clinical UpdatesMar 21, 2026

Predictive Power of MRI-Based Radiomic Dynamics for Pathological Complete Response in Hepatocellular Carcinoma: A Deep Learning Synthesis

Predictive Power of MRI-Based Radiomic Dynamics for Pathological Complete Response in Hepatocellular Carcinoma: A Deep Learning Synthesis

This review evaluates how deep learning-assisted delta radiomics on MRI, combined with AFP response, provides a non-invasive, high-accuracy prediction of pathological complete response in unresectable HCC undergoing conversion immunotherapy

Section: Clinical UpdatesMar 16, 2026

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion

A landmark study reveals that anti-BCMA bispecific antibodies, unlike anti-GPRC5D, deplete B-cell precursors from the small pre-B stage onward, explaining the significantly higher infection rates observed in multiple myeloma patients.

Section: Hematology-OncologyMar 13, 2026

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma

A breakthrough study reveals that the balance between FYN and LCK kinases acts as a metabolic switch in hepatocellular carcinoma. By modulating this axis through low-dose LCK inhibition, researchers successfully preserved T-cell stemness an

Section: GastroenterologyMar 12, 2026

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial

This post-hoc analysis of the HIMALAYA Phase III trial explores the link between immune-mediated adverse events and overall survival in unresectable HCC, revealing that patients on the STRIDE regimen who experienced imAEs had improved survi

Section: GastroenterologyMar 12, 2026

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma

The 3-year follow-up of the RATIONALE-309 trial demonstrates that first-line tislelizumab plus chemotherapy significantly improves overall survival (45.3 months) in recurrent or metastatic nasopharyngeal carcinoma, identifying B-cell signat

Section: newsMar 9, 2026

Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling

Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling

This review examines how low-dose gemcitabine and cisplatin (LDGC) synergize with anti-PD-L1 therapy in intrahepatic cholangiocarcinoma by reprogramming immunosuppressive SPP1+ macrophages and enhancing CD8+ T-cell cytotoxicity through STAT

Section: Clinical UpdatesMar 7, 2026

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease

The SURE-02 phase 2 trial demonstrates that a combination of sacituzumab govitecan and pembrolizumab achieves a 39% clinical complete response rate in muscle-invasive bladder cancer, offering a promising bladder-sparing alternative for pati

Section: newsMar 4, 2026

Three-Year RATIONALE-309 Data Confirm Sustained Survival Benefit of First-Line Tislelizumab in Nasopharyngeal Carcinoma

Three-Year RATIONALE-309 Data Confirm Sustained Survival Benefit of First-Line Tislelizumab in Nasopharyngeal Carcinoma

Long-term results from the RATIONALE-309 trial show tislelizumab plus chemotherapy significantly improves survival in recurrent or metastatic nasopharyngeal carcinoma, establishing a durable therapeutic standard and identifying B-cell signa

Section: newsMar 2, 2026

KEYVIBE-010: Why Adding TIGIT Inhibition to Pembrolizumab Failed to Benefit High-Risk Resected Melanoma Patients

KEYVIBE-010: Why Adding TIGIT Inhibition to Pembrolizumab Failed to Benefit High-Risk Resected Melanoma Patients

The Phase 3 KEYVIBE-010 trial demonstrates that adding vibostolimab to pembrolizumab in the adjuvant setting for melanoma does not improve outcomes, instead yielding a higher recurrence rate and increased toxicity, reinforcing pembrolizumab

Section: DermatologyMar 2, 2026

Redefining the Standard of Care in High-Risk Resected SCCHN: Insights from the GORTEC 2018-01 NIVOPOST-OP Trial

Redefining the Standard of Care in High-Risk Resected SCCHN: Insights from the GORTEC 2018-01 NIVOPOST-OP Trial

This review analyzes the Phase 3 NIVOPOST-OP trial, demonstrating that adding nivolumab to postoperative chemoradiotherapy significantly improves disease-free survival in high-risk SCCHN patients, establishing a potential new therapeutic st

Section: Clinical UpdatesMar 2, 2026

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice

A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specif

Section: newsFeb 20, 2026

Serplulimab Plus Chemotherapy Redefines First-Line Standards in Non-Squamous NSCLC: Results from the ASTRUM-002 Trial

Serplulimab Plus Chemotherapy Redefines First-Line Standards in Non-Squamous NSCLC: Results from the ASTRUM-002 Trial

The Phase 3 ASTRUM-002 trial demonstrates that adding serplulimab to chemotherapy significantly extends progression-free survival in non-squamous NSCLC, though the further addition of a bevacizumab biosimilar (HLX04) did not provide statist

Section: newsFeb 19, 2026

Prev 1 2 3 7 Next